Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [4607]

ESMO 2O23: Major pathologic response to neoadjuvant pembrolizumab in advanced melanoma trial exceeds 50 percent

ESMO 2O23: Major pathologic response to neoadjuvant pembrolizumab in advanced melanoma trial exceeds 50 percent

Lung cancer outcomes significantly improved with immunotherapy-based treatment given before and after surgery

Lung cancer outcomes significantly improved with immunotherapy-based treatment given before and after surgery

Does diabetes affect the survival of individuals with colorectal cancer?

Does diabetes affect the survival of individuals with colorectal cancer?

Skin cancer diagnoses using AI are as reliable as those made by medical experts

Skin cancer diagnoses using AI are as reliable as those made by medical experts

ESMO 2023: Amivantamab plus chemo with or without lazertinib reduced risk of disease progression or death for EGFR-mutated NSCLC

ESMO 2023: Amivantamab plus chemo with or without lazertinib reduced risk of disease progression or death for EGFR...

ESMO 2023: Lutetium (177Lu) vipivotide tetraxetan shows clinically meaningful and highly statistically significant rPFS benefit in patients with PSMA-positive mCRPC in the pre-taxane setting

ESMO 2023: Lutetium (177Lu) vipivotide tetraxetan shows clinically meaningful and highly statistically significant...

ESMO 2023: Cabozantinib dramatically improved progression-free survival in advanced neuroendocrine tumours

ESMO 2023: Cabozantinib dramatically improved progression-free survival in advanced neuroendocrine tumours

ESMO 2023: Kidney cancer study shows improved outcomes for patients with advanced disease when treated with belzutifan over everolimus

ESMO 2023: Kidney cancer study shows improved outcomes for patients with advanced disease when treated with...

ESMO 2023: Highest risk patients with clear-cell renal cell carcinoma benefit from adjuvant everolimus

ESMO 2023: Highest risk patients with clear-cell renal cell carcinoma benefit from adjuvant everolimus

ESMO 2023: Better use of existing drugs increases cervical cancer survival and reduces recurrence

ESMO 2023: Better use of existing drugs increases cervical cancer survival and reduces recurrence

More from ecancer